Abstract
De novo drug design is a computational technique to develop novel chemical
compounds from scratch without prior knowledge. Traditionally, structural
bioinformatics approaches used either structure-based or ligand-based design; the
former uses the active site information of the protein, and the latter uses known active
binders. Modern methods based on artificial intelligence help design de novo drugs in
less time by using pre-trained models. One of the major bottlenecks of the de novo drug
design is the synthetic feasibility of the active compounds, which is addressed using
AI-based methods that help reduce the time and cost of analysis of those compounds.
Recent success stories from several companies show the strength of the AI-based de
novo drug design programs, and many advances can be expected shortly.
Keywords: Artificial intelligence, Computer-aided drug design, Deep learning, Machine learning, Molecular docking, Scoring functions.
Related Journals
Recent Patents on Computer Science
The Chinese Journal of Artificial Intelligence
Current Chinese Computer Science
Journal of Fuzzy Logic and Modeling in Engineering
Recent Advances in Computer Science and Communications
International Journal of Sensors, Wireless Communications and Control
Journal of Intelligent Systems in Current Computer Engineering
Current E-Learning
Current Computer Science
Wireless and Communication Letters
Related Books
Computational Intelligence For Data Analysis
Applied Machine Learning and Multi-Criteria Decision-Making in Healthcare
A First Course in Artificial Intelligence
Artificial Intelligence: Models, Algorithms and Applications
Advanced Computing Techniques: Implementation, Informatics and Emerging Technologies
Handbook of Mobile Application Development: A Guide to Selecting the Right Engineering and Quality Features
Applications of Modern High Performance Networks
Arduino Meets Matlab: Interfacing, Programs and Simulink
Arduino and SCILAB based Projects
Application of Chaos and Fractals to Computer Vision